Skip to main content
Top
Published in: Diabetologia 1/2020

01-01-2020 | Cytokines | Article

Activation of the HIF1α/PFKFB3 stress response pathway in beta cells in type 1 diabetes

Authors: Hiroshi Nomoto, Lina Pei, Chiara Montemurro, Madeline Rosenberger, Allison Furterer, Giovanni Coppola, Brian Nadel, Matteo Pellegrini, Tatyana Gurlo, Peter C. Butler, Slavica Tudzarova

Published in: Diabetologia | Issue 1/2020

Login to get access

Abstract

Aims/hypothesis

The conserved hypoxia inducible factor 1 α (HIF1α) injury-response pro-survival pathway has recently been implicated in early beta cell dysfunction but slow beta cell loss in type 2 diabetes. We hypothesised that the unexplained prolonged prediabetes phase in type 1 diabetes may also be, in part, due to activation of the HIF1α signalling pathway.

Methods

RNA sequencing (RNA-Seq) data from human islets with type 1 diabetes or after cytokine exposure in vitro was evaluated for activation of HIF1α targets. This was corroborated by immunostaining human pancreases from individuals with type 1 diabetes for 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), the key effector of HIF1α-mediated metabolic remodelling, and by western blotting of islets and INS-1 832/13 cells exposed to cytokines implicated in type 1 diabetes.

Results

HIF1α signalling is activated (p = 4.5 × 10−9) in islets from individuals with type 1 diabetes, and in human islets exposed in vitro to cytokines implicated in type 1 diabetes (p = 1.1 × 10−14). Expression of PFKFB3 is increased fivefold (p < 0.01) in beta cells in type 1 diabetes and in human and rat islets exposed to cytokines that induced increased lactate production. HIF1α attenuates cytokine-induced cell death in beta cells.

Conclusions/interpretation

The conserved pro-survival HIF1α-mediated injury-response signalling is activated in beta cells in type 1 diabetes and likely contributes to the relatively slow rate of beta cell loss at the expense of early defective glucose-induced insulin secretion.
Appendix
Available only for authorised users
Literature
17.
go back to reference Liu W, Shen SM, Zhao XY, Chen GQ (2012) Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol 3:165–178PubMedPubMedCentral Liu W, Shen SM, Zhao XY, Chen GQ (2012) Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol 3:165–178PubMedPubMedCentral
20.
go back to reference Nomoto H, Gurlo T, Rosenberger M, Girgis MD, Dry S, Butler PC. Low grade islet but marked exocrine pancreas inflammation in an adult with autoimmune pre-diabetes. Case Rep Endocrinol (in press) Nomoto H, Gurlo T, Rosenberger M, Girgis MD, Dry S, Butler PC. Low grade islet but marked exocrine pancreas inflammation in an adult with autoimmune pre-diabetes. Case Rep Endocrinol (in press)
29.
go back to reference Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH (1999) Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1α. J Cell Sci 112:1203–1212PubMed Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH (1999) Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1α. J Cell Sci 112:1203–1212PubMed
Metadata
Title
Activation of the HIF1α/PFKFB3 stress response pathway in beta cells in type 1 diabetes
Authors
Hiroshi Nomoto
Lina Pei
Chiara Montemurro
Madeline Rosenberger
Allison Furterer
Giovanni Coppola
Brian Nadel
Matteo Pellegrini
Tatyana Gurlo
Peter C. Butler
Slavica Tudzarova
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2020
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-05030-5

Other articles of this Issue 1/2020

Diabetologia 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.